Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Ossium Health, Inc.
City of Hope Medical Center
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Juventas Cell Therapy Ltd.
Chinese PLA General Hospital
Chinese PLA General Hospital
Thomas Jefferson University
Chinese PLA General Hospital
Columbia University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
St. Petersburg State Pavlov Medical University
GC Cell Corporation
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Columbia University
Columbia University
Gruppo Italiano Malattie EMatologiche dell'Adulto
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
German CLL Study Group
UNC Lineberger Comprehensive Cancer Center
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
SCRI Development Innovations, LLC
University Health Network, Toronto
Roswell Park Cancer Institute
Arbeitsgemeinschaft medikamentoese Tumortherapie
National Cancer Institute (NCI)
Technical University of Munich
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center